Literature DB >> 25595832

Lessons from an outbreak of metallo-β-lactamase-producing Klebsiella oxytoca in an intensive care unit: the importance of time at risk and combination therapy.

S Vergara-López1, M C Domínguez2, M C Conejo3, Á Pascual4, J Rodríguez-Baño5.   

Abstract

BACKGROUND: Outbreaks of nosocomial infection due to carbapenem-resistant Enterobacteriaceae (CRE), mostly Klebsiella spp., have become a worldwide phenomenon. AIM: To investigate the risk factors for the acquisition of clonal multidrug-resistant Klebsiella oxytoca (MDRKO) producing the metallo-β-lactamase IMP-8 and hyperproducing chromosomal OXY-2 β-lactamase during a well-characterized outbreak, and to describe the clinical features of infections due to MDRKO.
METHODS: A four-wave outbreak due to MDRKO occurred in the intensive care unit of a Spanish hospital between 2009 and 2011. The risk factors for acquisition of MDRKO during waves 1 and 2 (in which colonized patients served as the main reservoir for the epidemic strain) were analysed using a case-control study by Cox regression and logistic regression analysis. Clinical data and treatments of patients infected with MDRKO were also analysed.
FINDINGS: For the study of risk factors, 26 cases and 45 controls were studied. None of the variables studied in the Cox regression analysis showed an association with MDRKO acquisition; time at risk was the only associated variable by logistic regression analysis. Colonization pressure was not associated with earlier acquisition. Overall, 14 patients were infected with MDRKO; ventilator-associated pneumonia (seven patients) was the most frequent type of infection. Monotherapy tended to be associated with higher mortality than combination therapy [60% (3/5) vs 16.6% (1/6); P = 0.07].
CONCLUSIONS: Time at risk was the most significant risk determinant for the acquisition of carbapenem-resistant Enterobacteriaceae (CRE) in this epidemiological context and should be included in any study of risk factors for the acquisition of multidrug-resistant bacteria. Combination therapy may be superior to monotherapy for the treatment of CRE infections.
Copyright © 2014 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Carbapenem-resistant Enterobacteriaceae; Klebsiella oxytoca; Outbreak; Time at risk

Mesh:

Substances:

Year:  2014        PMID: 25595832     DOI: 10.1016/j.jhin.2013.12.008

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  12 in total

1.  Characterization of Carbapenemase-Producing Klebsiella oxytoca in Spain, 2016-2017.

Authors:  María Pérez-Vazquez; Jesús Oteo-Iglesias; Pedro J Sola-Campoy; Hugo Carrizo-Manzoni; Verónica Bautista; Noelia Lara; Belén Aracil; Almudena Alhambra; Luis Martínez-Martínez; José Campos
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

Review 2.  Rapid separation of bacteria from blood-review and outlook.

Authors:  William G Pitt; Mahsa Alizadeh; Ghaleb A Husseini; Daniel S McClellan; Clara M Buchanan; Colin G Bledsoe; Richard A Robison; Rae Blanco; Beverly L Roeder; Madison Melville; Alex K Hunter
Journal:  Biotechnol Prog       Date:  2016-06-03

3.  A Systematic Review and Meta-analyses of the Clinical Epidemiology of Carbapenem-Resistant Enterobacteriaceae.

Authors:  Karlijn van Loon; Anne F Voor In 't Holt; Margreet C Vos
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

Review 4.  Klebsiella oxytoca and Emerging Nosocomial Infections.

Authors:  Nakul Neog; Upasana Phukan; Minakshi Puzari; Mohan Sharma; Pankaj Chetia
Journal:  Curr Microbiol       Date:  2021-03-03       Impact factor: 2.188

5.  Klebsiella oxytoca Complex: Update on Taxonomy, Antimicrobial Resistance, and Virulence.

Authors:  Jing Yang; Haiyan Long; Ya Hu; Yu Feng; Alan McNally; Zhiyong Zong
Journal:  Clin Microbiol Rev       Date:  2021-12-01       Impact factor: 50.129

6.  A hospital-based matched case-control study to identify risk factors for clinical infection with OXA-48-producing Klebsiella pneumoniae in rectal carriers.

Authors:  A Madueño; J Gonzalez Garcia; A Aguirre-Jaime; M Lecuona
Journal:  Epidemiol Infect       Date:  2017-07-17       Impact factor: 4.434

7.  Unusual carbapenem resistant but ceftriaxone and cefepime susceptible Klebsiella oxytoca isolated from a blood culture: Case report and whole-genome sequencing investigation.

Authors:  Shangxin Yang; Peera Hemarajata; Laura Shevy; Mario Maciariello; Karissa Culbreath; Karen Bush; Romney Humphries
Journal:  IDCases       Date:  2017-11-23

8.  Evaluation of automated systems for aminoglycosides and fluoroquinolones susceptibility testing for Carbapenem-resistant Enterobacteriaceae.

Authors:  Zhichang Zhao; Fangjun Lan; Maobai Liu; Weiyuan Chen; Liya Huang; Qili Lin; Bin Li
Journal:  Antimicrob Resist Infect Control       Date:  2017-08-01       Impact factor: 4.887

9.  Infections due to Carbapenem Resistant Enterobacteriaceae among Saudi Arabian Hospitalized Patients: A Matched Case-Control Study.

Authors:  M A Garbati; H Sakkijha; A Abushaheen
Journal:  Biomed Res Int       Date:  2016-04-06       Impact factor: 3.411

10.  Monotherapy versus combination therapy for multidrug-resistant Gram-negative infections: Systematic Review and Meta-Analysis.

Authors:  Adrian Schmid; Aline Wolfensberger; Johannes Nemeth; Peter W Schreiber; Hugo Sax; Stefan P Kuster
Journal:  Sci Rep       Date:  2019-10-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.